[Ip-health] Economic Times: Swiss drugmaker Roche launches costliest cancer drugs in India

Thiru Balasubramaniam thiru at keionline.org
Thu Nov 26 07:03:23 PST 2015


http://economictimes.indiatimes.com/articleshow/49927222.cms


Swiss drugmaker Roche launches costliest cancer drugs in India

By DIVYA RAJAGOPAL, ET Bureau | 26 Nov, 2015, 06.34AM IST



Read more at:
http://economictimes.indiatimes.com/articleshow/49927222.cms?from=mdr&utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

MUMBAI: As insurers, patients and governments across the world debate over
the rising cost of healthcare, Swiss pharmaceutical major Roche has boldly
launched two new drugs for late-stage breast cancer, pricing them higher
than any other cancer medicine in the Indian market.

Kadcyla and Perjeta, the new class of drugs launched in India in October,
cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively. ET
verified the price with several chemists and doctors, who said the maximum
discount that was available was in the range of Rs 10,000-15,000. Roche
said it gives the drugs free of cost after an initial stage of treatment.

Breast cancer is the leading cause of cancer death among Indian women.
Nearly 1.3 lakh women are diagnosed every year with the disease in India.
Kadcyla and Perjeta are prescribed for breast cancer patients tested
positive for the HER2 protein, which promotes the growth of cancer cells.

These drugs are given when the cancer becomes metastatic, or in simple
terms when the tumour spreads to other parts of the body where the chances
of cure are negligible. They are recommended when patients fail to respond
to Herceptin (trastuzumab), the most commonly prescribed treatment for
breast cancer

The cost of the drugs over a nine-month period hovers around Rs 12 lakh for
Kadcyla and Rs 30 lakh for Perjeta. In India, Roche collaborated with
Pune-based Emcure Pharmaceuticals to sell Herceptin under a local brand
name, Herclon, which costs about Rs 65,000 a vial.

Responding to ET's questions, Roche said it has a patient assistance
programme aimed at lowering the cost of treatment. "We at Roche believe
that access programmes need to be sustainable in order to have a
long-lasting impact," the company said in an email response. "Our
patient-assistance programme for Perjeta and Kadcyla is designed such that
patients only have to pay for finite cycles of therapy and hence the total
cost is significantly lowered," a Roche spokesperson said in an email
response .

Incidentally, last week, the National Institute of Health Care and
Excellence (NICE), an agency that is involved in guiding healthcare
improvement, has advised UK's National Health Service against including
Kadcyla in its reimbursement scheme citing a mismatch between price and
value.

The Indian government itself has taken note of high-priced cancer drugs and
signalled controls over those. More recently, Union Health Minister JP
Nadda unveiled the first outlet to supply low-cost cancer drugs at the All
India Institute of Medical Sciences in New Delhi. Oncologists in India
expressed their concerns over the high price tag that these drugs came
attached with.

"These newer drugs are prescribed after Herceptin fails. Any failure has no
cure. So I have to tell the patients that you might be getting three months
of extra life for spending Rs 20 lakh," said Dr Rajendra Badwe, surgical
oncologist at Mumbai's Tata Memorial Cancer Hospital (TMC). "It is a value
judgement that needs to be done, and the care giver is put into a big
dilemma of decision-making."

A leading oncologist from a public hospital in south India said he has not
encouraged patients to get on these drugs because of the price. "My
patients here cannot even afford Herceptin, so we have made it clear to the
patients about the price and the results that these drugs deliver," said
this oncologist who spoke on the condition of anonymity.

Kadcyla and Perjeta were approved by the US health regulator in 2013, after
trial results suggested an increased rate of survival in late-stage
patients compared with existing line of therapy. "In case of Kadcyla, it
was found in studies that the patients' average survival rate was 31 months
compared to 25 months on the single Tykerb-based treatment (another drug
used to treat breast cancer). For Perjeta, the survival rate was 56 months
versus 40 months seen with only Herceptin and chemothe ..

Since Herceptin is witnessing local competition, experts said Roche may be
looking to switch focus to the two new products. The company over the last
two years has cut down the price of Herceptin, after Biocon and partner
Mylan entered the market with their own biosimilar versions. In 2014,
Kadcyla and Perjeta were significant contributors to Roche's revenues, with
both posting average sales of $500 million globally.

In the past, drug companies have tried new approaches to create better
pricing points to make expensive medicines affordable to different levels
of income groups. Two years ago, for instance, Japanese firm Eisai launched
its breast cancer brand Halaven under a tiered pricing strategy tailored
for the Indian market.



More information about the Ip-health mailing list